Full bill text rendering is coming soon.
In the meantime, read the full text on Congress.gov ↗.
Core Policy Mechanism Top 1
Delay Medicare price negotiations when biosimilar entry imminent
Changes when Medicare can negotiate drug prices by automatically pausing or ending negotiations for a drug when a biosimilar version is expected on the market within two years, removing the negotiated price obligation for that period.
- Population Scope Medium Directly affects Medicare Part D enrollees who use high-cost biologic drugs subject to negotiation — a substantial but targeted subset of the ~67 million Medicare beneficiaries, estimated well under 25% of the U.S. population.
- Budgetary Magnitude Medium No funds are appropriated, but forgoing negotiated prices on high-cost biologics for one or more years represents recurring Medicare outlays that would otherwise have been reduced, producing a meaningful indirect fiscal effect without a discrete dollar figure in the bill.
- Legal / Regulatory Depth High Creates a new statutory mandate that automatically removes drugs from negotiation eligibility — a binding substantive constraint on the Secretary of Health and Human Services (HHS) that eliminates an existing enforceable pricing obligation for an entire class of products under defined conditions.
- Degree of Discretion Granted Medium The Secretary of HHS must make a factual determination of 'high likelihood' of biosimilar market entry, which involves judgment over uncertain commercial and regulatory timelines, but the downstream removal of negotiation status is mandatory once that finding is made.
- Implementation & Enforcement Burden Medium Imposes a recurring case-by-case adjudicatory obligation on HHS — pre-determination notice, written confirmation under penalty of perjury from manufacturers, and ongoing monitoring of biosimilar pipeline status — for each drug under negotiation consideration.
- Temporal Commitment High Amends the Social Security Act with no expiration date, persisting indefinitely until Congress affirmatively repeals or modifies it.
No signal yet
No possible riders have been surfaced for this bill.
Summary
This bill changes the rules for when Medicare can negotiate prices for certain drugs when a cheaper alternative called a biosimilar — a near-copy of a complex biological drug — is about to enter the market. Under current law, Medicare can negotiate lower prices for high-cost drugs. This bill delays or removes that negotiation process when a biosimilar is expected to become available within two years, on the theory that market competition from the biosimilar will drive down prices on its own.
AI-generated summary, pending human review.
| Version | Event | Date | User support | Your vote | Roll calls |
|---|---|---|---|---|---|
| Original |
Initial publication
Sep 28, 2026
|
Sep 28, 2026 | No votes yet | — | — |
Log in or create an account to record your vote on this legislation. Results are visible to all visitors.
Core Policy Mechanism Top 1
Delay Medicare price negotiations when biosimilar entry imminent
Changes when Medicare can negotiate drug prices by automatically pausing or ending negotiations for a drug when a biosimilar version is expected on the market within two years, removing the negotiated price obligation for that period.
- Population Scope Medium Directly affects Medicare Part D enrollees who use high-cost biologic drugs subject to negotiation — a substantial but targeted subset of the ~67 million Medicare beneficiaries, estimated well under 25% of the U.S. population.
- Budgetary Magnitude Medium No funds are appropriated, but forgoing negotiated prices on high-cost biologics for one or more years represents recurring Medicare outlays that would otherwise have been reduced, producing a meaningful indirect fiscal effect without a discrete dollar figure in the bill.
- Legal / Regulatory Depth High Creates a new statutory mandate that automatically removes drugs from negotiation eligibility — a binding substantive constraint on the Secretary of Health and Human Services (HHS) that eliminates an existing enforceable pricing obligation for an entire class of products under defined conditions.
- Degree of Discretion Granted Medium The Secretary of HHS must make a factual determination of 'high likelihood' of biosimilar market entry, which involves judgment over uncertain commercial and regulatory timelines, but the downstream removal of negotiation status is mandatory once that finding is made.
- Implementation & Enforcement Burden Medium Imposes a recurring case-by-case adjudicatory obligation on HHS — pre-determination notice, written confirmation under penalty of perjury from manufacturers, and ongoing monitoring of biosimilar pipeline status — for each drug under negotiation consideration.
- Temporal Commitment High Amends the Social Security Act with no expiration date, persisting indefinitely until Congress affirmatively repeals or modifies it.
No signal yet
Core Policy Mechanism
Delay Medicare price negotiations when biosimilar entry imminent
Incomplete vote
You have not made a selection on all required items:
Choose Neutral if you prefer not to commit. Leaving without completing will remove all your votes for this bill from the totals.
Maximum recommendations reached
You have already recommended the maximum number of components allowed on this bill. To recommend [new component], choose one of your current recommendations to unselect: